Cargando…

A translational approach to dystroglycanopathies: a frequent type of muscular dystrophy

Detalles Bibliográficos
Autores principales:	Cirak, Sebahattin, Wang, Haicui, Heredia, Raul, Muntoni, Francesco, Hathout, Yetrib, Herkenrath, Peter, Dötsch, Jörg, Nürnberg, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715192/ http://dx.doi.org/10.1186/2194-7791-2-S1-A27

Ejemplares similares

Zebrafish Fukutin family proteins link the unfolded protein response with dystroglycanopathies
por: Lin, Yung-Yao, et al.
Publicado: (2011)

Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy
por: Kanagawa, Motoi, et al.
Publicado: (2017)

LARGE expression in different types of muscular dystrophies other than dystroglycanopathy
por: Balci-Hayta, Burcu, et al.
Publicado: (2018)

Mendeliome sequencing enables differential diagnosis and treatment of neonatal lactic acidosis
por: Fazeli, Walid, et al.
Publicado: (2016)

Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)

Importance of Skin Changes in the Differential Diagnosis of Congenital Muscular Dystrophies
por: Yis, Uluç, et al.
Publicado: (2016)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy
por: Foltz, Steven J., et al.
Publicado: (2016)

Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report
por: Borisovna, Kondakova Olga, et al.
Publicado: (2019)

ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies
por: Cirak, Sebahattin, et al.
Publicado: (2013)

Mutations in INPP5K Cause a Form of Congenital Muscular Dystrophy Overlapping Marinesco-Sjögren Syndrome and Dystroglycanopathy
por: Osborn, Daniel P.S., et al.
Publicado: (2017)

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
por: Dang, Utkarsh J, et al.
Publicado: (2020)

Compound heterozygous POMT1 mutations in a Chinese family with autosomal recessive muscular dystrophy‐dystroglycanopathy C1
por: Hu, Pengzhi, et al.
Publicado: (2017)

Flow Cytometry for the Analysis of α-Dystroglycan Glycosylation in Fibroblasts from Patients with Dystroglycanopathies
por: Stevens, Elizabeth, et al.
Publicado: (2013)

Defining and identifying satellite cell-opathies within muscular dystrophies and myopathies
por: Ganassi, Massimo, et al.
Publicado: (2022)

Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation
por: Heywood, Wendy E., et al.
Publicado: (2016)

Tandem Mass Tag-Based Serum Proteome Profiling for Biomarker Discovery in Young Duchenne Muscular Dystrophy Boys
por: Alayi, Tchilabalo D., et al.
Publicado: (2020)

Abnormal Skeletal Muscle Regeneration plus Mild Alterations in Mature Fiber Type Specification in Fktn-Deficient Dystroglycanopathy Muscular Dystrophy Mice
por: Foltz, Steven J., et al.
Publicado: (2016)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Novel mutations in SLC6A5 with benign course in hyperekplexia
por: Dafsari, Hormos Salimi, et al.
Publicado: (2019)

Contribution of Dysferlin Deficiency to Skeletal Muscle Pathology in Asymptomatic and Severe Dystroglycanopathy Models: Generation of a New Model for Fukuyama Congenital Muscular Dystrophy
por: Kanagawa, Motoi, et al.
Publicado: (2014)

A Child of Congenital Muscular Dystrophy-Dystroglycanopathy with Homozygous Missense Variation in Exon 3 of the ISPD Gene: A Rare Case from Odisha
por: Biswal, Sebaranjan, et al.
Publicado: (2020)

Duchenne Muscular Dystrophy from Brain to Muscle: The Role of Brain Dystrophin Isoforms in Motor Functions
por: Wijekoon, Nalaka, et al.
Publicado: (2023)

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
por: Ayoglu, Burcu, et al.
Publicado: (2014)

TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020)

Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients
por: Capitanio, Daniele, et al.
Publicado: (2020)

Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy‐dystroglycanopathy
por: Dai, Yi, et al.
Publicado: (2018)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy
por: Kroon, Rosemarie H.M.J.M., et al.
Publicado: (2020)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018)

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2017)

Childhood onset limb-girdle muscular dystrophies in the Aegean part of Turkey
por: YİŞ, ULUÇ, et al.
Publicado: (2018)

Changes in Myonuclear Number During Postnatal Growth – Implications for AAV Gene Therapy for Muscular Dystrophy
por: Morgan, Jennifer, et al.
Publicado: (2021)

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
por: Rodger, Sunil, et al.
Publicado: (2012)

B3GALNT2 mutations associated with non-syndromic autosomal recessive intellectual disability reveal a lack of genotype–phenotype associations in the muscular dystrophy-dystroglycanopathies
por: Maroofian, Reza, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3l4ono2en4aoiqvf6tf84af3ds